A Phase I/II Study of Foretinib in Patients with Previously Treated Non-Small Cell Lung Cancer Receiving Standard Erlotinib Therapy (IND.196).
Phase of Trial: Phase I/II
Latest Information Update: 29 Mar 2016
At a glance
- Drugs Foretinib (Primary) ; Erlotinib
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- 15 Feb 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 03 Feb 2014 Planned End Date changed from 1 Dec 2013 to 1 Dec 2014 as reported by ClinicalTrials.gov record.
- 24 Jan 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.